When asked to describe the past 20 years of NeuroNexus, Rio describes the time as "transformative". "Building a company from the ground up involves innovative thinking and a forward-looking vision," he continues. "NeuroNexus has undergone a remarkable evolution over the past 20 years. During the challenging but exciting startup phase, we faced significant uncertainty about the viability of our business. Grant funding played a crucial role in supporting our early efforts. As we grew, we expanded our team and formed successful partnerships with major players like Philips Research." "Creating intellectual property was another milestone that added significant value to our company. This positioned us well for our eventual acquisition by Greatbatch, which elevated our discipline and knowledge as we became a subsidiary of a publicly traded medical device company. The experience of spinning out with Nuvectra, a spinal cord stimulation company, provided us with invaluable exposure to the medtech industry." "Eventually, we came full circle and identified an opportunity to acquire NeuroNexus, transforming it back into a private company. Throughout these transitions, our resilience, grit, and discipline guided us, positioning NeuroNexus today as stronger than ever."
NeuroNexus’ Post
More Relevant Posts
-
Big News: Edwards Acquires 2 Heart Device Companies! In a strategic move to amplify its suite of structural heart products, Edwards Lifesciences recently announced its plan to acquire two innovative cardiac device startups for a staggering $1.2 billion. This acquisition underscores Edwards' commitment to pioneering advanced solutions for heart disease. The first startup, JenaValve Technology, is on the cusp of transforming treatment for aortic regurgitation. Their Trilogy heart valve system is expected to receive FDA approval by late 2025, a significant milestone for both Edwards and patients who suffer from this condition. This acquisition extends Edwards' reach beyond its renowned transcatheter aortic valve replacement (TAVR) technology, promising new treatment horizons. The second acquisition, Endotronix, represents Edwards' foray into a novel therapeutic realm with its implanted pulmonary artery pressure sensor for managing heart failure. This technology could be revolutionary; precise monitoring of heart function is critical for patients battling heart failure. If certain milestones are achieved, an additional outlay of up to $445 million is anticipated, highlighting the potential growth in this yet underserved domain. For those of us in the recruitment business, this is a thrilling period. The expansion promises new opportunities and underscores the importance of staying ahead in talent acquisition for these breakthrough technologies. Let's keep the conversation going! What are your thoughts on these acquisitions? Comment below to share your insights! #MedicalDevices #HeartHealth #EdwardsLifesciences
-
Looking at the future of cardiac care, how can major device companies collaborate with the startup ecosystem? In this clip Chris Eso, Vice President, Global Head of Corporate and Business Development, M&A and Ventures at Medtronic, predicts that in the next 10-20 years, medical devices will be highly interconnected and data-driven. This shift marks a significant shift from traditional Medtech. Achieving this level of connectivity will require extensive collaboration between major device companies and the startup ecosystem. The full panel shares insights on fostering successful partnerships, enhancing patient care, and driving the next wave of breakthroughs in cardiac treatment and management. Tune into the full panel “Accelerating Cardiac Care Innovation: How Can Major Device Companies Collaborate with the Startup Ecosystem?” to hear more from Ken Nelson, Nate Harrington, Lisa Suennen, GCB.D, Chris Eso, and David Hochman.
-
Q4 M&A Moves: MedTech is on Fire! 🔥 With acquisitions heating up, major players are positioning for 2025. Here’s a look at some bold moves: • Boston Scientific x Cortex: Bringing in advanced mapping tech for AFib treatment, setting new standards in cardiac care. • Merit Medical Systems, Inc. x Cook Medical: Expanding cardiovascular capabilities through lead management solutions. • Johnson & Johnson x V-Wave: Reinforcing its structural heart portfolio with innovative interatrial shunt tech. • Hologic, Inc. x Gynesonics, Inc.: Transforming women’s health with new, minimally invasive fibroid treatments. With more deals expected before year’s end, it’s clear: MedTech leaders are betting big on strategic growth and innovation. Which acquisition stands out to you?
-
-
🧠 INBRAIN Neuroelectronics secures $50m funding to advance its BCI technology New investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and Avançsa, and existing investors Asabys Partners, Aliath Bioventures and Vsquared participated in the financing round. In addition to the Series B round, which brings its total investment to $68m, the company also secured additional funding and support from Germany-based Merck. The partnership aims to advance its technology platform for human use, across both central and peripheral nervous system applications, said the medical technology company. Read more online: https://lnkd.in/e5rYDKHZ 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing
-
-
My first podcast! I had so much fun with Kyle Kruse 🚀 and Richard Meiklejohn talking about Imricor and how we are advancing medicine with our technology. Thanks guys for the invitation! The link is below if you are interested in learning about what we are doing.
Innovation Leader - Hospital Innovation - Healthcare Ventures - Medtech Impact - Global Scot
Imricor Medical Systems is advancing the electrophysiology field by allowing physicians to perform cardiac ablation procedures in the growing number of interventional magnetic resonance (iCMR) suites found or being developed in leading hospitals. In this episode of the #MedtechImpactPodcast, we are joined by Imricor’s Global Sales Leader, Greg Englehardt, to share the journey and their mission of bringing not just a set of innovative surgical tools to market, but also an entirely new operating environment! Where other large companies have tried and failed, Greg details how the company has navigated an array of technical challenges to make their solution successful. Between gaining Imricor’s CE mark approval and navigating a product launch during the pandemic, combined with Greg’s extensive experience with startups, this discussion is packed with insights. If you want to learn more about their upcoming US market development and how you could be part of a growing team then be sure to tune in so you can be informed and inspired. https://lnkd.in/e7q7fbVk #CardiacAblation #MRI #Medtech #Startups #KeepInnovating Kyle Kruse 🚀, Steve Wedan, Jonathon Gut, Gregg Stenzel, Jennifer Weisz, Dan Sunnarborg, Nick Corkill, Nick Twohy, Katherine Lindborg, Vic Fabano, Nazem Akoum, Ram Kumar, Giovanni Leo, Martin S. Maron, MD, Ali Tavallaei, Ph.D., P.Eng., Ding S He, Scott Hutton, Bob Andrews, ☤ Srijoy Mahapatra, MD, Anna Koulova, Hamid Ghanbari, Atul Gupta, MD, Megan Friedlander, Alan Oslan, Prasanth Ganesan, Markus Rottmann, Kathleen Nowicke, Milen Ivanov, David McManus.
-
We are pleased and honored to announce that the Tokio based Kaneka corporation, has aquired EndoStream Medical Ltd., marking the first and very successful exit for Galil Ofek Innovation Fund. EndoStream, specializes in innovative technologies for cerebrovascular diseases and has developed the Nautilus™ device for treating cerebral aneurysms. This acquisition underscores the strength of Israel's medical device sector and the value of our investment strategy. This milestone reflects GO Innovation commitment to nurturing groundbreaking medical technologies that address critical healthcare needs. Danel Mayer Israel Innovation Authority Eyal Aviram EndoStream Medical
-
Director of Electrophysiology | Wharton School of Finance/ University of Pennsylvania | Private Equity Consultant | Assistant Professor | Board Advisor | MedTech Founder | TAMPA2 MAZE cofounder
The J.P. Morgan Healthcare conference and networking events (shout out to The Wharton School Healthcare night) in #SanFrancisco were incredibly impactful. Of particular relevance were discussions around emerging #meddevice and #biopharma startups, reports on recent #cardiovascular devices driving tremendous value for large strategics, and most importantly #innovation that will impact patients and their well being. #JPM25 #JPM2025 #JPMWeek #medtech #CV #healthcare #healthinnovation
-
Zynex's bold expansion in patient monitoring technologies moves from vision to reality. 🚀 Growth vs. Value: The Investor's Dilemma 🚀 When choosing between growth and value, investors often find themselves in a tricky balancing act. Growth demands vision and patience, while value offers a more predictable, steady return. But what if you could have both? 🔄 Take Zynex Inc. (Nasdaq: ZYXI) as a case study. Known for its non-opioid pain management solutions, Zynex has a solid business generating strong revenues and profit, but now it’s aiming for something bigger: patient monitoring. This new market, valued at $3.6 billion, represents a massive growth opportunity for Zynex. Founder and CEO, Thomas Sandgaard, who started Zynex nearly 30 years ago, believes in scaling revenues from $200M in 2024 to $800M in the coming years. The company’s current portfolio boasts an impressive 80% gross margin, and they’ve seen a 20% rise in order growth while expanding their tech portfolio. With FDA-approved devices and innovative new products on the way, the long-term upside is undeniable. 💡 Why This Matters to Investors. Long-term growth: Zynex is reinvesting in patient monitoring, aiming to disrupt the market with new tech, including the revolutionary NiCO CO-oximeter. Strong foundation: Zynex’s existing business continues to generate cash, providing a stable base for its ambitious growth plans. A balanced risk-reward: Ladenburg Thalmann’s target price is 3x the current share price – showcasing strong potential upside. The combination of growth and value makes Zynex an intriguing opportunity for forward-looking investors. 📈 Read the entire article by clicking the following link: https://lnkd.in/gd-P7RJV Zynex Medical | Zynex Monitoring Solutions | Nasdaq | Proactive #Investing #GrowthStocks #ValueStocks #Zynex #NASDAQ #MedicalTech
-
-
Neurent Medical, a medtech firm from Galway, has secured €9 million in growth capital from Claret Capital, with support from the Ireland Strategic Investment Fund (ISIF). This funding is part of a larger €18.2 million deal closed in September. The investment will facilitate Neurent Medical's expansion into the U.S. market, focusing on developing innovative therapies for treating chronic nasal conditions. Recognized as one of Ireland's promising medtech companies, Neurent has now raised approximately €50 million to advance its medical solutions. #MedTech #StartupFunding #HealthcareInnovation #NeurentMedical #USExpansion
-
-
Neurent Medical, a medtech firm from Galway, has secured €9 million in growth capital from Claret Capital, with support from the Ireland Strategic Investment Fund (ISIF). This funding is part of a larger €18.2 million deal closed in September. The investment will facilitate Neurent Medical's expansion into the U.S. market, focusing on developing innovative therapies for treating chronic nasal conditions. Recognized as one of Ireland's promising medtech companies, Neurent has now raised approximately €50 million to advance its medical solutions. #MedTech #StartupFunding #HealthcareInnovation #NeurentMedical #USExpansion
-
